Highlights

  • 4DMedical launched the CLEAR clinical evidence program targeting the US pulmonary embolism market, expanding the obtainable US market for CT:VQ to US$3 billion.
  • A binding agreement to acquire Austria-based contextflow establishes an immediate European commercial footprint, adding CE-marked lung cancer screening and insurance reimbursement contracts in Germany.
  • A commercial contract with SimonMed Imaging across more than 170 US outpatient centres marks the company's entry into the US outpatient imaging market on commercial terms from day one.

 

4DMedical Limited (ASX:4DX) is a Melbourne-based global respiratory imaging technology company whose core product, CT:VQ, is a software platform designed to measure lung function using conventional CT scanners — without the radiation exposure or logistical complexity associated with traditional nuclear medicine ventilation-perfusion (VQ) scans. The company also offers LDAf, a lung density analysis tool, as part of its functional imaging suite. 4DMedical has positioned itself at the intersection of diagnostic radiology and functional pulmonary medicine, addressing a gap in the market where conventional imaging modalities have struggled to deliver quantifiable ventilation and perfusion data efficiently. The period from late May to early June 2026 produced three significant corporate announcements in rapid succession, each targeting a distinct dimension of the company's global growth ambition.

The CLEAR Program: Unlocking a US$3 Billion Market Opportunity

On 2 June 2026, 4DMedical announced the launch of CLEAR, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism. The program is a clinical evidence initiative designed to fast-track the regulatory and commercial pathway for CT:VQ into the acute pulmonary embolism (PE) market in the United States. PE is a life-threatening condition caused by blood clots in the lungs and is currently diagnosed predominantly through CT pulmonary angiography (CTPA), a contrast-based imaging approach. The existing nuclear VQ market processes approximately one million scans per annum in the US, but the much larger CTPA-dominated PE imaging market accounts for approximately five million scans annually.

By positioning CT:VQ as a head-to-head alternative to CTPA in acute PE diagnosis — with the advantage of being contrast-free — 4DMedical is attempting to address a considerably larger addressable market than previously targeted. The combined opportunity across the nuclear VQ and CTPA segments is estimated by the company at US$3 billion in the United States alone, up from the previously articulated US$2.5 billion figure. The core study underpinning CLEAR is a multi-centre, multinational, prospective, observational trial comparing CT:VQ with CTPA in patients with suspected PE. Mass General Brigham (MGB) affiliated teaching hospitals have been engaged as the lead clinical site, lending scientific credibility and institutional weight to the program.

European Expansion: The contextflow Acquisition

One day before the CLEAR announcement, on 1 June 2026, 4DMedical disclosed a binding agreement to acquire contextflow GmbH, an Austrian medical technology company specialising in lung cancer screening and advanced AI-driven thoracic imaging. The acquisition price comprises upfront payments of approximately A$18.56 million in cash plus 56,235 ordinary shares, with an earnout of up to 2.59 million zero exercise price options over two years subject to performance milestones. The deal also retains approximately EUR 19.0 million — or roughly AU$30.8 million — in accumulated tax losses, providing a meaningful economic uplift to the transaction economics.

The strategic rationale is to acquire an established European presence without the time and capital cost of building a greenfield operation. contextflow provides 4DMedical with a Vienna-based team, existing commercial relationships, regulatory infrastructure, and a CE-marked lung cancer screening solution powered by lung nodule detection technology. Importantly, the acquired business holds insurance reimbursement contracts in Germany, which represents the largest market in Europe for healthcare services and a market where reimbursement infrastructure is critical to scaling a clinical imaging product. The transaction positions 4DMedical across three continents — North America, Europe, and Australia and New Zealand — for the first time, representing a material expansion of operational scale and market access.

SimonMed Agreement: Commercial Momentum in US Outpatient Imaging

The third significant announcement, made on 29 May 2026, was the execution of a commercial agreement with SimonMed Imaging, one of the United States' largest and most geographically distributed outpatient imaging providers with more than 170 centres across 10 states. Unlike prior agreements which involved research, evaluation, or pilot frameworks, the SimonMed contract delivers immediate clinical deployment of both CT:VQ and LDAf on commercial terms from day one, generating revenue from the outset. This distinction is material for investors assessing the commercialisation timeline of 4DMedical's technology.

SimonMed is also described as a partner in building the reimbursement evidence base for CT:VQ across both public and private payers in the US. Reimbursement coverage remains the critical bottleneck for widespread adoption of CT:VQ in the American healthcare system, as without established CPT codes and payer contracts, clinical interest does not automatically translate into billable procedures. The SimonMed partnership provides a scaled, real-world environment in which the company can generate the outcomes data that payers will require to assess coverage decisions.

Financial Context and Investment in Pro Medicus

In the context of recent financial filings, it is worth noting that Pro Medicus Limited disclosed in its interim results for 1H FY2026 that it made a $10 million hybrid debt and equity investment in 4DMedical Limited in July 2025. Pro Medicus subsequently recorded unrealised gains of $149.1 million before tax on that investment by the end of December 2025, implying a substantial re-rating of 4DMedical's perceived enterprise value over that period. While this is a valuation signal embedded in a third-party's accounts rather than a direct 4DMedical financial metric, it reflects significant market enthusiasm around the company's technology prospects during the second half of 2025.

Conclusion

4DMedical has entered June 2026 in a markedly different strategic position compared to six months prior. The CLEAR program frames a credible pathway to a US$3 billion addressable market, the contextflow acquisition delivers an immediate European commercial platform, and the SimonMed contract establishes real commercial traction in the US outpatient setting. Each of these initiatives carries execution risk, and clinical outcomes, reimbursement developments, and integration progress will all be critical variables over the next 12 to 24 months. For investors and analysts with an interest in early-stage ASX medical technology companies, 4DMedical's rapid strategic expansion makes it a name that warrants close monitoring.